NFKB1 and acute kidney injury: Furthermore, proteasome inhibitors have the potential to reduce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) levels in the nucleus, leading to VEGF inhibition, which is identified as one of the potential pathological factors contributing to TMA associated with AKI, potentially predisposing to TMA [47].